BMI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Badger Meter is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is in a clear post-earnings downtrend, fundamentals weakened in the latest quarter, analysts have been cutting targets, and there is no strong proprietary buy signal. I would not buy it now; the better call is to avoid or sell until growth and momentum improve.
BMI is technically weak despite a modest MACD improvement. The stock closed at 122.04, below the prior close of 122.56, with regular session weakness of -0.96%. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), which points to a broader downtrend. RSI_6 at 45.7 is neutral, so it is not oversold enough to signal an attractive entry. Price is sitting near pivot support at 121.20, with immediate support at 117.95 and resistance at 124.46. The near-term pattern data also skews weak, with limited upside and negative next-day/month expectations.
["RBC and Baird still maintain Outperform/positive ratings, implying some belief in a second-half recovery.", "Management and some analysts expect a second-half acceleration after project timing delays.", "The acquisition of UK-based UDlive could improve competitiveness in sewer monitoring over time.", "MACD histogram is positive and expanding, suggesting short-term momentum may be stabilizing."]
["Q1 2026 EPS missed estimates and signaled financial stress.", "Revenue fell 8.97% YoY, net income fell 28.81% YoY, EPS fell 28.46% YoY, and gross margin declined.", "Utility water sales dropped 10% YoY due to project timing and weaker municipal orders.", "The stock fell more than 24% after earnings, confirming strong negative market reaction.", "Kessler Topaz and Pomerantz investigations create an event-driven overhang.", "Maxim downgraded the stock to Hold and cut EPS estimates significantly.", "Barclays remains Underweight and says the stock still screens expensive versus muted growth.", "Technical trend remains bearish with SMA_200 > SMA_20 > SMA_5."]
Latest quarter: Q1 2026. The company posted declining growth across the board: revenue fell to $202.277M, down 8.97% YoY; net income fell to $27.335M, down 28.81% YoY; EPS came in at $0.93, down 28.46% YoY; gross margin slipped to 41.69%, down 2.93 points YoY. This is not the kind of growth profile that supports a confident long-term buy today.
Analyst sentiment has weakened recently. Maxim downgraded BMI to Hold and cut EPS estimates. RBC, Baird, JPMorgan, and Stifel still have constructive or positive ratings, but several of them lowered price targets after Q1 results. Barclays is Underweight and also cut its target sharply. Overall, Wall Street is split, but the recent trend is toward lower targets and more caution, which is negative for near-term upside. Pros: some firms still see second-half acceleration and maintain Outperform/Buy-type views. Cons: multiple target cuts, a downgrade to Hold, and concerns that growth guidance looks optimistic.
